T	TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) RLL-124CIPUS											
In F	In Re Application Of: Rampal et al.											
Serial No. Filing Date Examiner Group Art U 09/973,265 10/9/2001 unknown unknown												
09/973,265 10/9/2001 unknown unknown												
Ti	Title: A STABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING OMEPRAZOLE											
			Ass	sistant Cor	Address to: mmissioner fo gton, D.C. 202		•	50				
			,	37 (CFR 1.97(b)	ı		3				
1.	1. Image: The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.											
2.		The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:										
	☐ the statement specified in 37 CFR 1.97(e);											
OR												
		☐ the fee se	et forth in 37 CFR 1.17(p).								

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) Docket No. RLL-124CIPUS											
AIPE.											
In Re Application: Rampal et al.											
Serial No.	Filing Date 10/9/2001		Examiner		Group Art Unit						
09/973,265	10/9/2001	RAVENIN	unknown		unknown						
A STABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING OMEPRAZOLE											
Payment of Fee											
(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))											
☐ A check in the amount of is attached.											
			e and credit Deposi	it Acco	unt No.						
	☐ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No.										
as described below. A duplicate copy of this sheet is enclosed.											
Charge the amount of											
Credit any overpayment.											
Charge any additional fee required.											
Certificate of	Certificate of Transmission by Facsimile* Certificate of Mailing by First Class Mail										
I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No.) on (Date) I certify that this document and fee is being deposited on February 4, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.											
	Signature		Signature of Pers	san Mail	ing Correspondence						
Christine Kenedy											
Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate											
*This certificate madeposit account.	*This certificate may only be used if paying by deposit account.										
Dated: February 4, 2002											
Signature Jayadeep R. Deshmukh, Esq., Reg. No. 34,507											
Ranbaxy Pharmaceuticals											
600 College Road East, Su											
Princeton, New Jersey 085											
Telephone: (609) 720-562											
Facsimile: (609) 514-9779											
(007) 014 7/17											
cc.											

INFORMATION DESCLOSURE CITATION

Form PTO-1449

Docket No.: RLL-124 JPUS | Serial No.: 09/973,265

Applicants: Rampal et al

Filed: 10/09/2001

Group:

	A THAT I THAT WAS	U.S. P.	ATENT DOCUMENTS		,		
EXAMINER INITIAL DOCUMENT NUMBER		DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	4,255,431	3/10/81	Junggren et al.	424	263		
	4,628,098	12/9/86	Nohura et al.	546	271		
	4,758,579	7/19/88	Kohl et al.	514	338		
	4,786,505	11/22/88	Lovgren et al.	424	468		
	5,178,867	1/12/93	Guittard et al.	424	473		
	5,385,739	1/31/95	Debregeas et al.	424	494		
	5,626,875	5/6/97	Ballester Rodes et al.	424	464		
	6,077,541	6/20/00	Chen et al.	424	480		
	6,096,340	8/1/00	Chen et al.	424	480		
		FOREIGN	PATENT DOCUMENTS	i			
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	0 519 365 A1	6/13/92	EPO			Abstract only	
	05-194225	8/3/93	Japan				
	WO 96/01623	12/25/96	PCT				
	WO 97/12580	4/10/97	PCT				
	WO 97/12581	4/10/97	PCT				
	WO 99/61022	12/2/99	PCT				
	OTHER DOCUME	NTS (Includ	ding Author, Title, Date, P	ertinent P	ages, Etc.)		
		 					
							

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NFORMATION DISCLOSURE CITATION

Docket No.: RLL-124 July US Serial No.: 09/973,265

Applicants: Rampal et al

Group:

TLU TLU		*/							
FOREIGN PATENT DOCUMENTS									
	M	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		
		WO 00/12064	3/9/00	PCT					
		WO 00/78284	12/28/00	PCT			L		
							_		

Filed: 10/09/2001

	٦.
EXAMINEI	4

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.